Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug

U.S. stock index futures jumped on Wednesday after Gilead Sciences said its experimental antiviral drug met the main goal of a trial testing it in COVID-19 patients......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Gilead Sciences Inc. said Wednesday morning that a government-run clinical trial evaluating its experimental drug remdesivir in certain COVID-19 patie.....»»

As businesses across the United States continue to feel the pressure from the Covid-19 coronavirus pandemic, Cody Johnson expects his company will see a 20% growth in revenue this year. After just three months as CEO at Houston-based National Signs, Joh.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Shares of Gilead Sciences Inc. were down 5.3% in trading on Thursday after a Stat News report said a draft of the clinical trial results for remdesivir, an experimental drug being tested as a treatment for COVID-19, showed that the drug did not spe.....»»

As businesses across the United States continue to feel the pressure from the Covid-19 coronavirus pandemic, Cody Johnson expects his company will see a 20% growth in revenue this year. After just three months as CEO at Houston-based National Signs, Joh.....»»

Friday's market surge on signs of a promising COVID-19 drug on partial data shows the 'casino mentality' of today's markets, says Mercadien Asset Management's Ken Kamen......»»

Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise......»»

Gilead Sciences shares surged Friday morning following a media report detailing encouraging partial data from trials of the biotech company's experimental drug remdesivir in severe COVID-19 patients. Fred Katayama reports......»»

Shares of Gilead Sciences Inc rose 10% in early trading on Friday after a report that patients with COVID-19 treated with the company's experimental drug, remdesivir, in a clinical trial showed rapid recovery in fever and respiratory symptoms......»»

Gilead Sciences Inc's shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients......»»

University of Chicago Medicine researchers said they saw “rapid recoveries” in 125 COVID-19 patients taking Gilead Sciences Inc.’s experimental drug remdesivir as part of a clinical trial, according to Stat News......»»

US Futures Soar On Report Of Positive Results From Gilead Drug US equity futures are soaring after-hours following headlines from STAT news that Gilead Sciences' experimental COVID-19 vaccine drug remdesivir is  â€.....»»

Temple University Hospital said Wednesday it has started the first clinical trial in the United States testing an experimental therapy known as gimsilumab as a potential coronavirus treatment. Gimsilumab, a type of drug known as a fully human monoclonal.....»»

Gilead’s experimental drug remdesivir shows ‘hopeful’ signs in small group of coronavirus patients.....»»

Gilead’s experimental drug remdesivir shows `hopeful’ signs in small group of coronavirus patients.....»»

Gilead Sciences Inc. has cut in half the time it takes to make its signature, but experimental, COVID-19 treatment, a critical step in the process of treating some of the 1.3 million people infected by the novel coronavirus that causes the disease. .....»»

Aiming to accelerate treatments against COVID-19 into mid-stage clinical trials in three to five months, Vir Biotechnology Inc. said Monday that it signed a collaboration with drug giant GlaxoSmithKline that includes a $250 million equity stake in t.....»»

Sarah .....»»